A statement released earlier today by Vetr Inc. about Juno Therapeutics Inc (NASDAQ:JUNO) bumps the target price to $38.02
- Updated: September 17, 2016
Reporting a possible upside of 0.14%, Vetr Inc. bumped the estimated target of Juno Therapeutics Inc (NASDAQ:JUNO) to $38.
Previously on Friday August 5 2016, Maxim Group released a statement about Juno Therapeutics Inc(NASDAQ:JUNO) dropped the target price from $80.00 to $50.00 that suggested an upside of 0.57%.
Only yesterday Juno Therapeutics Inc (NASDAQ:JUNO) traded 2.44% higher at $33.39. The company’s 50-day average is $31.26 and its two hundred day moving average is $37.34. The last stock price close is down 20.20% from the two hundred day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. Trade volume was was up over the average, with 3,237,577 shares of JUNO changing hands over the typical 2,187,880 shares..
See Graphic Below:
Juno Therapeutics Inc has a 52 week low of $22.37 and a 52 week high of $57.82 and has a market cap of $0.0.
A total of 11 equity analysts have released a report on Juno Therapeutics Inc. Zero rate the stock a strong buy, 0 rate the stock a buy, 0 analysts rate the company a hold, 0 rate the company to underperform, and lastly 0 firmsrate the company as sell with a 12-month target stock price of $55.73
General Company Details For Juno Therapeutics Inc (NASDAQ:JUNO)
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, and a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.